Life Sciences Tools and Services
Company Overview of AltheaDx, Inc.
AltheaDx, Inc. operates as a molecular diagnostics company that specializes in the field of pharmacogenetics in the United States. The company’s algorithm-based bioinformatic platform and pharmacogenetics (PGx) product testing portfolio serve as a tool to assist healthcare providers in identifying optimal drugs for their patients, as well as dosing guidelines based on a patient’s genetic make-up, current prescription regimen, and other key factors. It designs IDgenetix, a PGx testing portfolio that enables healthcare providers to make timely and evidence-based decisions. The company also offers research and development services that provide a start-to-finish suite of tools focused on molecul...
3550 Dunhill Street
San Diego, CA 92121
Founded in 1998
Key Executives for AltheaDx, Inc.
Chief Executive Officer and Director
Co-Founder and Co-Chairperson of the Board
Senior Vice President of Regulatory Affairs & Quality Assurance
Compensation as of Fiscal Year 2014.
AltheaDx, Inc. Key Developments
AltheaDx, Inc. Announces Appointment Noah Nasser as Senior Vice President of Sales, Effective February 2, 2015
Jan 22 15
AltheaDx, Inc. announced the appointment of Noah Nasser as Senior Vice President of Sales, effective February 2, 2015. Mr. Nasser will report to Greg Hamilton, Chief Executive Officer of AltheaDx. Mr. Nasser brings more than 20 years of commercial and managerial experience within the diagnostic, medical device and life science fields. Prior to joining AltheaDx, Mr. Nasser was the Global Sales Leader for Verinata Health. As Vice President of Sales and Market Development at Verinata, Mr. Nasser was responsible for global commercialization of the verifi® prenatal test.
AltheaDx Mulls Acquisitions
Dec 22 14
AltheaDx, Inc. has filed an IPO in the amount of $69 million and intends to use the proceeds for research and development, including clinical studies to demonstrate the utility of its products and support reimbursement efforts, as well as expansion of its IDgenetix testing portfolio, to expand its commercial capabilities in selling and marketing related to our IDgenetix tests, for expansion of our facilities and laboratory operations and the remaining proceeds for working capital and other general corporate purposes.
AltheaDx, Inc. Announces Executive Appointments
Dec 1 14
AltheaDx, Inc. announced the appointment of Dr. Juan-Sebastian Saldivar as Chief Medical Officer. Additionally, the company announced the appointment of Dr. Mark Gold to the board of directors. Prior to joining the company, Dr. Saldivar served as Vice President of Clinical Services and Medical Affairs at Sequenom Laboratories. From July 2003 to March 2012, Dr. Saldivar filled various roles including Director of Molecular Diagnostics at City of Hope National Medical Center, while also teaching as a Clinical Associate Professor in the Department of Pathology from January 2010 to March 2012. Dr. Saldivar also served as Director of Clinical Laboratory Services at Perlegen Sciences, Inc., from February 2009 to November 2009. Dr. Gold has more than four decades of experience in basic research, clinical research and translating research into clinical practice, and has been a pioneer in translational neuroscience research for more than three decades. From 1990 until his retirement in June 2014 he was a Professor and Chairman at the University of Florida. He has served as a consultant to banks, private equity firms, global pharmaceutical companies, and venture capital firms on devices, pharmaceuticals and health care delivery. He has served on the boards of directors of Viewray, Inc., and AxoGen, Inc.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|